Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 Genitourinary Cancers Symposium /
Basal subtype predicts clinical benefit from neoadjuvant chemo in urothelial cancer

26th - 28th Feb 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 27.02.15
Views: 2435

Dr Arlene Siefker-Radtke - MD Anderson Cancer Centre, Houston, USA

Dr Siefker-Radtke talks to ecancertv at ASCO GU 2015 about the results of a phase II clinical trial of DDMVAC plus bevacizumab and the merits of using basal subtyping to individualise treatment approaches.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation